Royan Ajay 4
4 · Adagio Therapeutics, Inc. · Filed Aug 12, 2021
Insider Transaction Report
Form 4
Royan Ajay
Director
Transactions
- Conversion
Common Stock
2021-08-10+9,244,580→ 9,244,580 total(indirect: See Footnote) - Conversion
Series A Preferred Stock
2021-08-10−1,250,000→ 0 total(indirect: See Footnote)→ Common Stock (6,250,000 underlying) - Conversion
Series B Preferred Stock
2021-08-10−176,304→ 0 total(indirect: See Footnote)→ Common Stock (881,520 underlying) - Conversion
Series C Preferred Stock
2021-08-10−422,612→ 0 total(indirect: See Footnote)→ Common Stock (2,113,060 underlying) - Purchase
Common Stock
2021-08-10$17.00/sh+1,997,000$33,949,000→ 11,241,580 total(indirect: See Footnote)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into 5 shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.
- [F2]These shares are held of record by Mithril II LP ("II LP"). Mithril II UGP LLC ("UGP II") is the general partner of Mithril II GP LP ("GP II") and GP II is the general partner of II LP. The Reporting Person, a member of the Issuer's board of directors, is the sole managing member of UGP II and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by II LP. The Reporting Person is one of two members of the investment committee of GP II. The investment committee makes all investment decisions with respect to shares held by II LP and may be deemed to have shared voting, investment and dispositive power with respect to such shares. The Reporting Person disclaims beneficial ownership of the shares held by II LP, except to the extent of the Reporting Person's pecuniary interest therein, if any.